STADA brings in Biogen exec to head Specialty business

German generics and consumer healthcare major STADA Arzneimittel (SAZ: Xetra) has appointed former Biogen (Nasdaq: BIIB) biosimilars head Ian Henshaw to the STADA executive committee (SEC) as executive vice president (EVP) and global head of Specialty.

This enables current global head of Specialty and member of the SEC, Bryan Kim, to assume responsibility for STADA’s largest region, Western Europe, with immediate effect.

STADA noted that Mr Henshaw is a successful executive who has more than 30 years of industry experience and a great network within the area. Most recently, he operated with full end-to-end responsibility as senior VP and global head biosimilars at Biogen, where he in total spent 10 years. Prior to that, Mr Henshaw worked for more than six years at The Medicines Company, covering emerging markets, neurocritical care, and business development, having started his career at Eli Lilly (NYSE: LLY). Additionally, he served as non-executive director at South Korea’s Samsung Bioepis, a biopharmaceutical company with a focus on biosimilars in different therapeutic areas.